Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
A safety study of Remsima SC for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis remains active but not rec…
-
EMA approval · 2026-03-30EMA Authorised: Imuldosa (ustekinumab) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Imuldosa (ustekinumab) from Accord Healthcare S.L.U. for Crohn's disease, psoriasis, and psoriatic …
-
EMA approval · 2026-03-30EMA Authorised: Uzpruvo (ustekinumab) — Stada Arzneimittel AG
EMA authorised Uzpruvo (ustekinumab) for the treatment of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug [Phase 3]
Phase 3 study evaluating Sonelokimab for Psoriatic arthritis in biologic DMARD-naive patients; the study is currently ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response [Phase 3]
Phase 3 clinical trial update on sonelokimab for active psoriatic arthritis in patients with inadequate response to anti-TNFα therapy; recru…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Korean Post-marketing Surveillance for Xeljanz XR
Korean post-marketing surveillance study for Xeljanz XR (tofacitinib extended-release) is currently recruiting to monitor safety and effecti…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis [NA]
A clinical trial update from the University of Pennsylvania on preventing cardiovascular disease and mortality in patients with psoriasis or…
-
CLINICAL_TRIALS withdrawal · 2026-03-27Clinical Trial Update: Pregnancy and Medically Assisted Conception in Rare Diseases
Clinical trial NCT02450396 on pregnancy and medically assisted conception in rare autoimmune diseases has been withdrawn.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Preventing Structural Damage in Early Psoriatic Arthritis [Phase 4]
This clinical trial update notes a Phase 4 study in early psoriatic arthritis to prevent structural damage, currently recruiting and sponsor…
-
EMA approval · 2026-03-20EMA Authorised: Apremilast Accord (apremilast) — Accord Healthcare S.L.U.
The EMA has authorised Accord Healthcare's apremilast product (Apremilast Accord) for psoriatic arthritis, psoriasis, Behçet's syndrome, and…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of Picankibart in Patients With Active Psoriatic Arthritis [Phase 2, Phase 3]
Clinical trial update indicating a Phase 2/3 study of Picankibart in active psoriatic arthritis is currently recruiting.
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Biobank for Inflammatory Chronic Diseases and Osteoporosis
The Biobank for Inflammatory Chronic Diseases and Osteoporosis study is currently recruiting and will collect samples from patients with inf…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis [Phase 3]
Takeda's Phase 3 continuation study of Zasocitinib in adults with psoriatic arthritis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
Clinical trial update evaluating injection site pain and adherence when switching from a low to high concentration AVT-02 (adalimumab) acros…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
Pfizer is conducting a post-marketing surveillance study in Korea to monitor the safety of tofacitinib (Xeljanz) in pediatric patients with …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis [NA]
A clinical trial update describing the planned evaluation of a self-management smartphone app intended to improve safety skills in adults wi…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) [Phase 3]
This Phase 3 INSPIRE 2 trial compares tildrakizumab with placebo in anti-TNF-naïve adults with active psoriatic arthritis, reporting on effi…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
A Cairo University-led study is recruiting to evaluate nutritional status in rheumatic diseases and its association with disease activity ac…
-
CLINICAL_TRIALS safety_alert · 2026-03-09Clinical Trial Update: A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
A regulatory study assessing the effectiveness of additional risk minimization measures for ARAVA (Leflunomide) in Saudi Arabia. It focuses …
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
A Costa Rican registry study evaluating IL-23 inhibitors for psoriasis and psoriatic arthritis; the trial is not yet recruiting.
-
FDA approval · 2026-03-06FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc, introducing the extended-r…
-
FDA approval · 2026-03-06FDA Approved: SKYRIZI — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for SKYRIZI (risankizumab-rzaa) from AbbVie Inc. The action updates or expands the drug's regulatory…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease [Phase 1]
Phase 1 study of S-4321 in autoimmune and immune-mediated diseases; the trial status is not yet recruiting.
-
EMA approval · 2026-03-05EMA Authorised: Simponi (golimumab) — Janssen Cilag International NV
The European Medicines Agency authorised Simponi (golimumab) for multiple inflammatory conditions including rheumatoid arthritis, psoriatic …